Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biomira submits Tru-Scint in Canada

This article was originally published in Clinica

Executive Summary

Biomira has made a New Drug Submission to the Canadian Health Protection Branch for its Tru-Scint AD imaging agent. The submission covers the detection of recurrent breast cancer and primary, residual or recurrent ovarian cancer. The Canadian agency has indicated it will give the technetium-99m-labelled monoclonal antibody priority evaluation status, since the active substance may provide more effective diagnosis of serious and life threatening diseases than currently used protocols.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts